Biogen (BIIB) Stock: Gains On Positive Real-World Treatment Data

Biogen Inc (NASDAQ: BIIB) is having an incredibly strong time in the pre-market hours this morning, and for good reason. The company released data showing positive real-world experiences among patients using its leading MS therapies. As a result, investor excitement ensued and the stock found its way upward. As is almost always the case, our partners at Trade Ideas were the first to alert us to the movement. At the moment (8:32), LLY is trading at $275.31 per share after a gain of $2.37 per share or 0.87% thus far today.

BIIB Releases Positive Real-World Data

As mentioned above, Biogen is having a strong time in the pre-market hours after releasing positive real-world treatment data. The data came from the company’s leading MS therapies known as TECFIDERA(R) and TYSABRI(R). The company showed that when treated early in the course of the disease improved outcomes were seen in patients living with relapsed multiple sclerosis. According to the data, initiating the appropriate disease modifying therapy soon after diagnosis has been shown to slow the physical and cognitive decline associated with the disease, allowing these patients to stay active longer. In a statement, Kate Dawson, M.D., vice president of US Medical at BIIB had the following to offer…

The new real-world TECFIDERA and TYSABRI data presented at AAN emphasize the importance of effective treatment early in the course of one’s disease… Timely treatment with appropriate therapies can help mitigate damage caused by MS and delay long-term disability for people with the disease.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on BIIB. In particular, we’re interested in following TECFIDERA and TYSABRI to see if this positive data leads to expanded sales. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

For sidebar:

[Image Courtesy of Wikimedia]

Leave a Comment